ATOS

Atossa Therapeutics, Inc.

Price Chart

Latest Quote

$2.22

-0.13 (-5.53%)

Current Price

Previous Close	$2.35
Open	$2.36
Day High	$2.38
Day Low	$2.16
Volume	309,424

Fetched: 2026-06-17T12:40:13

Stock Information

Shares Outstanding	9.97M
Cash Equivalents	$31.72M
Net Income	$-37.64M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$22.14M
EPS (TTM)	$-4.37
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-12.60M
Income	$-37.64M
Book/sh	$3.54
Cash/sh	$3.18
Employees	16

Financial Ratios

Quick Ratio	4.25
Current Ratio	4.92

Returns & Margins

ROA	-45.54%
ROE	-78.58%

Ownership

Insider Ownership	1.85%
Institutional Ownership	16.30%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-0.51
P/B	0.63

Analyst Data

Recommendation	strong_buy
Target Price	$22.00

Technical Indicators

SMA20	$nan
SMA50	$nan
SMA200	$nan
RSI	9.86
ATR	nan

Shares Float	8.58M
Short Float	4.66%
Short Ratio	7.93
Volatility	1.15
Rel Volume	1.71

Performance History

Week	nan%
Month	nan%
Quarter	nan%
6 Months	nan%
YTD	nan%
Year	nan%
3 Years	nan%
5 Years	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-16	$nan	309,424
2026-06-15	$2.35	477,300
2026-06-12	$2.46	644,400
2026-06-11	$2.59	1,419,900
2026-06-10	$4.40	29,900
2026-06-09	$4.41	53,900
2026-06-08	$4.55	36,000
2026-06-05	$4.47	80,900
2026-06-04	$4.85	46,800
2026-06-03	$4.70	45,100
2026-06-02	$4.85	77,700
2026-06-01	$5.11	58,500
2026-05-29	$5.23	42,900
2026-05-28	$5.19	51,700
2026-05-27	$5.12	39,800
2026-05-26	$4.95	30,300
2026-05-22	$4.96	28,200
2026-05-21	$4.97	55,000
2026-05-20	$4.84	38,800
2026-05-19	$4.75	50,600
2026-05-18	$4.78	42,700

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

📰 Latest News

Top Midday Decliners

MT Newswires • 2026-06-11T17:47:05Z

Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment

Proactive • 2026-06-10T16:51:44Z

We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully

Simply Wall St. • 2026-02-09T13:44:18Z

New Strong Sell Stocks for Oct. 22

Zacks • 2025-10-22T10:31:00Z

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Simply Wall St. • 2025-09-02T13:30:09Z

Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity

Insider Monkey • 2025-07-03T02:03:08Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$37,141,000	$27,621,000	$31,377,000	$27,691,000
Other Income Expense	$-6,000	$-1,933,000	$-3,060,000	$-146,000
Other Non Operating Income Expenses	$-6,000	$-223,000	$-70,000	$-146,000
Net Non Operating Interest Income Expense	$2,377,000	$4,050,000	$4,343,000	$877,000
Operating Expense	$37,141,000	$27,621,000	$31,377,000	$27,691,000
General And Administrative Expense	$15,956,000	$13,504,000	$14,043,000	$12,608,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Net Interest Income	$2,377,000	$4,050,000	$4,343,000	$877,000
Interest Income	$2,377,000	$4,050,000	$4,343,000	$877,000
Normalized Income	$-34,770,000	$-23,794,000	$-27,104,000	$-26,960,000
Net Income From Continuing And Discontinued Operation	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Total Operating Income As Reported	$-37,141,000	$-27,621,000	$-31,377,000	$-27,691,000
Net Income Common Stockholders	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Net Income	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Net Income Including Noncontrolling Interests	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Net Income Continuous Operations	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Pretax Income	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Special Income Charges	$0	$-1,710,000	$-2,990,000	$0
Interest Income Non Operating	$2,377,000	$4,050,000	$4,343,000	$877,000
Operating Income	$-37,141,000	$-27,621,000	$-31,377,000	$-27,691,000
Per Share
Diluted EPS	$-4.04	$-3.04	$-3.60	$-3.15
Basic EPS	$-4.04	$-3.04	$-3.60	$-3.15
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-37,125,000	$-25,894,000	$-28,364,000	$-27,683,000
Total Unusual Items	$0	$-1,710,000	$-2,990,000	$0
Total Unusual Items Excluding Goodwill	$0	$-1,710,000	$-2,990,000	$0
Reconciled Depreciation	$16,000	$17,000	$23,000	$8,000
EBITDA (Bullshit earnings)	$-37,125,000	$-27,604,000	$-31,354,000	$-27,683,000
EBIT	$-37,141,000	$-27,621,000	$-31,377,000	$-27,691,000
Diluted Average Shares	$8,611,320	$8,390,617	$8,405,440	$8,441,600
Basic Average Shares	$8,611,320	$8,390,617	$8,405,440	$8,441,600
Diluted NI Availto Com Stockholders	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Tax Provision	$0	$0	$0	$0
Write Off	$0	$1,710,000	$2,990,000	$0
Research And Development	$21,185,000	$14,117,000	$17,334,000	$15,083,000
Selling General And Administration	$15,956,000	$13,504,000	$14,043,000	$12,608,000
Other Gand A	$15,956,000	$13,504,000	$14,043,000	$12,608,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Total Assets	$47,608,000	$76,444,000	$96,252,000	$123,532,000
Total Non Current Assets	$1,990,000	$1,987,000	$4,033,000	$5,335,000
Other Non Current Assets	$1,990,000	$1,987,000	$2,323,000	$635,000
Current Assets	$45,618,000	$74,457,000	$92,219,000	$118,197,000
Other Current Assets	$133,000	$119,000	$62,000	$1,207,000
Restricted Cash	$110,000	$110,000	$110,000	$110,000
Prepaid Assets	$4,076,000	$3,144,000	$3,587,000	$5,247,000
Cash Cash Equivalents And Short Term Investments	$41,299,000	$71,084,000	$88,460,000	$110,890,000
Cash And Cash Equivalents	$41,299,000	$71,084,000	$88,460,000	$110,890,000
Investmentin Financial Assets	-	$0	$1,710,000	$4,700,000
Receivables	-	-	$0	$743,000
Taxes Receivable	-	-	$0	$743,000
Goodwill And Other Intangible Assets	-	-	-	-
Debt
Total Debt	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$8,255,000	$4,967,000	$5,236,000	$5,568,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$0
Current Liabilities	$8,255,000	$4,967,000	$5,236,000	$5,568,000
Other Current Liabilities	$1,097,000	$1,507,000	$1,803,000	$19,000
Payables And Accrued Expenses	$6,265,000	$1,929,000	$2,063,000	$4,265,000
Payables	$4,293,000	$679,000	$806,000	$2,965,000
Accounts Payable	$4,293,000	$679,000	$806,000	$2,965,000
Equity
Common Stock Equity	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Total Equity Gross Minority Interest	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Stockholders Equity	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Retained Earnings	$-246,562,000	$-211,792,000	$-186,288,000	$-156,194,000
Long Term Equity Investment	-	-	-	$4,700,000
Other
Treasury Shares Number	$88,003	$88,003	$88,003	-
Ordinary Shares Number	$8,611,361	$8,611,333	$8,353,604	$8,441,600
Share Issued	$8,699,364	$8,699,336	$8,441,607	$8,441,600
Tangible Book Value	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Invested Capital	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Working Capital	$37,363,000	$69,490,000	$86,983,000	$112,629,000
Total Capitalization	$39,353,000	$71,477,000	$91,016,000	$117,964,000
Treasury Stock	$1,475,000	$1,475,000	$1,475,000	$0
Additional Paid In Capital	$285,840,000	$283,194,000	$255,987,000	$251,366,000
Capital Stock	$1,550,000	$1,550,000	$22,792,000	$22,792,000
Common Stock	$1,550,000	$1,550,000	$22,792,000	$22,792,000
Preferred Stock	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$893,000	$1,531,000	$1,370,000	$1,284,000
Current Accrued Expenses	$1,972,000	$1,250,000	$1,257,000	$1,300,000
Investments And Advances	-	$0	$1,710,000	$4,700,000
Available For Sale Securities	-	-	$1,710,000	$4,700,000
Capital Lease Obligations	-	-	-	-
Current Capital Lease Obligation	-	-	-	-
Net PPE	-	-	-	-
Accumulated Depreciation	-	-	-	-
Gross PPE	-	-	-	-
Machinery Furniture Equipment	-	-	-	-

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-29,785,000	$-21,049,000	$-20,955,000	$-20,787,000
Operating Activities
Operating Cash Flow	$-29,762,000	$-21,030,000	$-20,941,000	$-20,760,000
Cash Flow From Continuing Operating Activities	$-29,762,000	$-21,030,000	$-20,941,000	$-20,760,000
Operating Gains Losses	-	$7,000	-	$3,000
Investing Activities
Capital Expenditure	$-23,000	$-19,000	$-14,000	$-27,000
Investing Cash Flow	$-23,000	$-19,000	$-14,000	$-4,727,000
Cash Flow From Continuing Investing Activities	$-23,000	$-19,000	$-14,000	$-4,727,000
Financing Activities
Financing Cash Flow	$0	$3,673,000	$-1,475,000	$0
Cash Flow From Continuing Financing Activities	$0	$3,673,000	$-1,475,000	$0
Repurchase Of Capital Stock	-	$0	$-1,475,000	$0
Net Common Stock Issuance	-	$0	$-1,475,000	$0
Issuance Of Capital Stock	-	-	-	$0
Common Stock Issuance	-	-	-	$0
Net Other Financing Charges	-	-	-	-
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
End Cash Position	$41,409,000	$71,194,000	$88,570,000	$111,000,000
Beginning Cash Position	$71,194,000	$88,570,000	$111,000,000	$136,487,000
Changes In Cash	$-29,785,000	$-17,376,000	$-22,430,000	$-25,487,000
Proceeds From Stock Option Exercised	$0	$3,673,000	$0	$0
Net PPE Purchase And Sale	$-23,000	$-19,000	$-14,000	$-27,000
Purchase Of PPE	$-23,000	$-19,000	$-14,000	$-27,000
Change In Working Capital	$2,346,000	$448,000	$1,519,000	$-599,000
Change In Other Working Capital	$-304,000	$208,000	$129,000	$341,000
Change In Other Current Liabilities	$-410,000	$-296,000	$1,784,000	$-2,000
Change In Other Current Assets	$4,000	$331,000	$-1,697,000	$-597,000
Change In Payables And Accrued Expense	$4,002,000	$-181,000	$-2,245,000	$2,103,000
Change In Accrued Expense	$388,000	$-54,000	$-86,000	$855,000
Change In Payable	$3,614,000	$-127,000	$-2,159,000	$1,248,000
Change In Account Payable	$3,614,000	$-127,000	$-2,159,000	$1,248,000
Change In Prepaid Assets	$-946,000	$386,000	$3,548,000	$-2,773,000
Stock Based Compensation	$2,646,000	$2,292,000	$4,621,000	$6,788,000
Asset Impairment Charge	$0	$1,710,000	$2,990,000	$0
Depreciation Amortization Depletion	$16,000	$17,000	$23,000	$8,000
Depreciation And Amortization	$16,000	$17,000	$23,000	$8,000
Depreciation	$16,000	$17,000	$23,000	-
Net Income From Continuing Operations	$-34,770,000	$-25,504,000	$-30,094,000	$-26,960,000
Common Stock Payments	-	$0	$-1,475,000	$0
Net Investment Purchase And Sale	-	-	$0	$-4,700,000
Purchase Of Investment	-	-	$0	$-4,700,000
Change In Receivables	-	-	$743,000	$329,000

Fetched: 2026-06-15